Multipurpose Prevention Technologies (MPTs): a promising response to current challenges around hormonal contraceptive methods & HIV
08 March 2016
This panel session provided an overview of recent data on various hormonal contraceptive methods and HIV acquisition in HIV-negative women and gave an update of current evidence on drug interactions between various contraceptive hormones and specific antiretroviral (ARV) drugs. The session also highlighted the market access work being done by the IMPT and efforts to ensure that MPTs will be desirable, acceptable, and accessible to women and adolescent girls once commercially available. A live webinar with highlights from the presentations was held on 8 March 2016.
Moderator: Kirsten Vogelsong (Bill & Melinda Gates Foundation)
Vogelsong, K., Polis, C., Hemmerling, A., & Dellplain, L.